Emergence of SARS-CoV-2 with Dual-Drug Resistant Mutations During a Long-Term Infection in a Kidney Transplant Recipient.
Yoko TaninoKeisuke NishiokaChie YamamotoYohei WatanabeTomo DaidojiMasataka KawamotoSayaka UdaShoko KiritoYuta NakagawaYu KasamatsuYoshiyuki KawaharaYuri SakaiShuji NoboriTohru InabaBon OtaNaohisa FujitaAtsushi HoshinoYoko NukuiTakaaki NakayaPublished in: Infection and drug resistance (2024)
Drug-resistant variants with double mutations (S:E340K/RdRp:V791I) became dominant within 23 days after starting treatment, suggesting that even a combination therapy involving sotrovimab and RDV, dual-drug resistant viruses may emerge rapidly in immunocompromised patients. The dual-resistant variants had lower virus yields than those of the wild-type virus in vitro, suggesting that they paid a fitness cost.
Keyphrases
- drug resistant
- combination therapy
- multidrug resistant
- acinetobacter baumannii
- sars cov
- wild type
- end stage renal disease
- chronic kidney disease
- copy number
- ejection fraction
- newly diagnosed
- physical activity
- prognostic factors
- body composition
- intensive care unit
- cystic fibrosis
- extracorporeal membrane oxygenation
- mechanical ventilation
- respiratory failure
- patient reported